BCPC Stock Analysis: Balchem | NASDAQ
Specialty Chemicals | NASDAQ, USA | Market Cap: 5.560m USD | 12M Return: 14.1% | US0576652004 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 52.6M
EPS Trend: 99.3%
Qual. Beats: 0
Rev. Trend: 97.8%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Balchem Corporation (NASDAQ: BCPC) is a U.S. specialty ingredients manufacturer serving nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. The company operates three reportable segments: Human Nutrition and Health (food and beverage systems, vitamin K2, microencapsulation, choline nutrients), Animal Nutrition and Health (microencapsulated ruminant supplements, methylsulfonylmethane, choline chloride, chelated minerals), and Specialty Products (ethylene oxide and propylene oxide for healthcare sterilization and fumigation, chelated minerals for high-value crops). Balchem sells through a direct sales force, independent distributors, and sales agents. As a specialty chemicals company, Balchems business model centers on proprietary encapsulation and chelation technologies used to produce higher-margin functional additives rather than commodity chemicals, with diversified end-market exposure helping to offset demand swings in any single industry. The company was incorporated in 1967 and is headquartered in Montvale, New Jersey.
- EPA ethylene oxide rules pressure medical sterilization revenue
- Animal Nutrition choline demand rises with dairy and livestock output
- Specialty ingredient pricing offsets raw material cost inflation
| Net Income: 170.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA 2.46 > 1.0 |
| NWC/Revenue: 21.71% < 20% (prev 21.44%; Δ 0.27% < -1%) |
| CFO/TA 0.13 > 3% & CFO 223.8m > Net Income 170.9m |
| Net Debt (94.6m) to EBITDA (275.0m): 0.34 < 3 |
| Current Ratio: 2.47 > 1.5 & < 3 |
| Outstanding Shares: last quarter (32.0m) vs 12m ago -2.05% < -2% |
| Gross Margin: 36.46% > 18% (prev 35.82%; Δ 0.64% > 0.5%) |
| Asset Turnover: 65.92% > 50% (prev 61.02%; Δ 4.90% > 0%) |
| Interest Coverage Ratio: 26.13 > 6 (EBIT TTM 226.2m / Interest Expense TTM 8.66m) |
| A: 0.14 (Total Current Assets 404.9m - Total Current Liabilities 164.1m) / Total Assets 1.70b |
| B: 0.74 (Retained Earnings 1.25b / Total Assets 1.70b) |
| C: 0.13 (EBIT TTM 226.2m / Avg Total Assets 1.68b) |
| D: 3.52 (Book Value of Equity 1.33b / Total Liabilities 376.8m) |
| Altman-Z'' = 7.93 = AAA |
| DSRI: 1.01 (Receivables 145.6m/131.5m, Revenue 1.11b/1.01b) |
| GMI: 0.98 (GM 35.82% / 36.46%) |
| AQI: 0.95 (AQ_t 0.57 / AQ_t-1 0.60) |
| SGI: 1.09 (Revenue 1.11b / 1.01b) |
| TATA: -0.03 (NI 170.9m - CFO 223.8m) / TA 1.70b) |
| Beneish M = -3.00 (Cap -4..+1) = A |
As of November 10, 2026, the stock is trading at USD 175.99 with a total of 280,137 shares traded. Over the past week, the price has changed by +0.80%, over one month by +4.86%, over three months by -0.68% and over the past year by +14.07%.
Current recommended Stop Loss: 168.30 (which is 4.4% or 1.7 ATR below the current price).
Balchem has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy BCPC.
- StrongBuy: 1
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 213.5 | 21.3% |
P/E Trailing = 32.9113
P/E Forward = 29.7619
P/S = 5.014
P/B = 4.1869
P/EG = 2.9788
Revenue TTM = 1.11b USD
EBIT TTM = 226.2m USD
EBITDA TTM = 275.0m USD
Long Term Debt = 124.0m USD (from longTermDebt, last quarter)
Short Term Debt = 3.98m USD (from shortTermDebt, last quarter)
Debt = 160.9m USD (from shortLongTermDebtTotal, last quarter) + Leases 18.4m
Net Debt = 94.6m USD (calculated: Debt 160.9m - CCE 66.3m)
Enterprise Value = 5.66b USD (5.56b + Debt 160.9m - CCE 66.3m)
Interest Coverage Ratio = 26.13 (Ebit TTM 226.2m / Interest Expense TTM 8.66m)
EV/FCF = 27.24x (Enterprise Value 5.66b / FCF TTM 207.6m)
FCF Yield = 3.67% (FCF TTM 207.6m / Enterprise Value 5.66b)
FCF Margin = 18.72% (FCF TTM 207.6m / Revenue TTM 1.11b)
Net Margin = 15.41% (Net Income TTM 170.9m / Revenue TTM 1.11b)
Gross Margin = 36.46% ((Revenue TTM 1.11b - Cost of Revenue TTM 704.6m) / Revenue TTM)
Gross Margin QoQ = 36.37% (prev 36.51%)
Tobins Q-Ratio = 3.32 (Enterprise Value 5.66b / Total Assets 1.70b)
Interest Expense / Debt = 5.38% (Interest Expense 8.66m / Debt 160.9m)
Taxrate = 22.47% (49.5m / 220.4m)
NOPAT = 175.4m (EBIT 226.2m * (1 - 22.47%))
Current Ratio = 2.47 (Total Current Assets 404.9m / Total Current Liabilities 164.1m)
Debt / Equity = 0.12 (Debt 160.9m / totalStockholderEquity, last quarter 1.33b)
Debt / EBITDA = 0.34 (Net Debt 94.6m / EBITDA 275.0m)
Debt / FCF = 0.46 (Net Debt 94.6m / FCF TTM 207.6m)
Total Stockholder Equity = 1.29b (last 4 quarters mean from totalStockholderEquity)
RoA = 10.16% (Net Income 170.9m / Total Assets 1.70b)
RoE = 13.21% (Net Income TTM 170.9m / Total Stockholder Equity 1.29b)
RoCE = 15.97% (EBIT 226.2m / Capital Employed (Equity 1.29b + L.T.Debt 124.0m))
RoIC = 11.79% (NOPAT 175.4m / Invested Capital 1.49b)
WACC = 6.19% (E(5.56b)/V(5.72b) * Re(6.25%) + D(160.9m)/V(5.72b) * Rd(5.38%) * (1-Tc(0.22)))
Discount Rate = 6.25% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -82.25 | Cagr: -0.84%
[DCF] Terminal Value 77.97% ; FCFF base≈189.2m ; Y1≈216.9m ; Y5≈319.2m
[DCF] Fair Price = 147.7 (EV 4.80b - Net Debt 94.6m = Equity 4.71b / Shares 31.9m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 99.33 | EPS CAGR: 14.60% | SUE: 0.64 | # QB: 0
Revenue Correlation: 97.82 | Revenue CAGR: 7.23% | SUE: 0.26 | # QB: 0
EPS current Quarter (2027-03-31): EPS=1.48 | Chg30d=+3.15% | Revisions=+25% | Analysts=2
EPS current Year (2026-12-31): EPS=5.87 | Chg30d=+0.61% | Revisions=+40% | GrowthEPS=+14.1% | GrowthRev=+9.2%
EPS next Year (2027-12-31): EPS=6.36 | Chg30d=+1.47% | Revisions=+40% | GrowthEPS=+8.3% | GrowthRev=+5.9%
[Analyst] Revisions Ratio: +62% (up=5, down=0)